VIVUS — Investor Presentation (January 2019)
24 slides from VIVUS's investor presentation, Jan 7, 2019
Slide 1: Forward Looking Statements; Non-GAAP Financial Measures
Forward Looking Statements Non-GAAP Financial Measures ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 2 Forward Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subje
Slide 2: Contents
Contents ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 3 •OverviewPage 4 •PharmaceuticalsPage 7 •AcquisitionsPage 14 •DebtPage 17 •FinancialsPage 19 •Strategic DevelopmentPage 21
Slide 3: Brief Overview of Company
Overview Brief Overview of Company HISTORY RESET GROWTH 1991 – Apr 30th, 2018 May 1st, 2018 – June 30th, 2018 – Hard Reset July 1st, 2018 – Future • Founded as sexual health biopharmaceutical and device company • IPO’ed in 1993 • Company had four products approved • Multiple CEO’s • Activist Shareho
Slide 4: Investment Highlights
Overview Investment Highlights This is the first quarter VIVUS generated positive EBITDA based on bond almost two years ahead of schedule performance, VIVUS expects to be able to address the remaining structured sales force QYSMIA ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 5
Slide 5: Management Focus Next Months
Overview Management Focus Next 24 Months ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 6 •Drive Qsymia revenue and profitability with the Transformative Pharmaceutical Operating Model •Re-launch PANCREAZE in Q1 2019 •New sales team and excellent market insights •Leverage the Tr
Slide 6: Management Team
Overview Management Team • McKesson, BMS, OTN, BVCF, ORIX, Willow • Johnson & Johnson, Novartis, KRIM, Willow • Deloitte and Touche, Alexza Pharmaceuticals, Pharmacyclics, Incyte, • Wilson, Sonsini, Goodrich and Rosati P.C. • Glaxo Smith Kline, ICC, Novartis • Elan, Merck, Schering Plough, Sanofi Av
Slide 7: Pharmaceutical Assets
Pharmaceuticals Pharmaceutical Assets Track and Breakthrough Therapy designation ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 8 Pre-Clinical Phase 1 Phase 2 Phase 3 Approved PANCREAZE® -EPI due to Cystic Fibrosis + other conditions Qsymia® -Obesity (Planned EU refiling based o
Slide 8: Qsymia is a safe and effective therapy for BMI management
Pharmaceuticals Qsymia is a safe and effective therapy for body mass index management Proprietary extended-release formulation combining low doses of active ingredients from two previously approved compounds, phentermine and topiramate We believe the 3-month data from our CONQUER study supports shor
Slide 9: PANCREAZE for exocrine pancreatic insufficiency
Pharmaceuticals • PANCREAZE is indicated for exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions Pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreas glands Provides proven benefits to EPI patients Indicated for both pediat
Slide 10: STENDRA for erectile dysfunction
Pharmaceuticals • STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 11 Generics Market Due to Viagra and Cialis going off Patent US, South America, Canada and India Rights were sol
Slide 11: VI-0106 PAH
Pharmaceuticals VI-0106 PAH • Tacrolimus for the Treatment of Pulmonary Arterial Hypertension (PAH) ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 12 PAH is a serious, rare, and progressive disease Progressive narrowing in pulmonary arteries, resulting in right heart failure and
Slide 12: PAH Clinical Overview
Pharmaceuticals PAH Clinical Overview The progressive narrowing in pulmonary arteries leading to heart failure ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 13
Slide 13: Worldwide Market for PAH Therapies
VIVUS Pharmaceuticals Worldwide Market for PAH Therapies $4 500 $4 000 $3,500 $3,000 $2500 $2,.000 $1 500 $1,000 $500 $-Adempas Adcirca Revatio Opsun1.it Letairis Tracleer •orentiram •Tyvaso •Ren1odulin •ventavis Flolan 0.._', C/J Q ;.:= ..... ...... ] ::s ...... 2007 2008 2009 2010 2011 Year 2012 2
Slide 14: Tacrolimus Experience in PAH patients
Pharmaceuticals Tacrolimus Experience in PAH patients ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 15 •Compassionate use •3 end-stage patients, WHO functional class 3 and 4 •Positive impact on clinical outcomes •Dramatically reduced rate of hospitalizations •Functional class i
Slide 15: Asset Acquisition Philosophy
Acquisitions Asset Acquisition Philosophy ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 16 •As a core VIVUS activity, we are evaluating additional in-licensing and acquisition candidates that would meet our goals of meeting patients’ needs while working toward profitability and
Slide 16: Corporate Debt Alternatives
Debt Corporate Debt Alternatives ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 17 In order of current preference 1 Improve operating performance to generate enough recurring cash flow to pay down and refinance debt 2 Acquire asset(s) that generate $25M - $40M of annual non-GAAP
Slide 17: Debt Bridge January 2019 to May 2020
Debt Debt Bridge January 2019 to May 2020 $350 $300 Senior Debt $250 New Senior $200 Cash Used $150 $100 New Second Lien $50 Convertible Debt $0 $291.4M of Total Debt Nov 2018 $181.4M Pay Off Convertible Debt May 2020 $216.4M Total Debt May 31st 2020 • As of May 2020, based on current internal proje
Slide 18: VIVUS Health Platform
Strategic Development VIVUS HEALTH PLATFORM ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 19 • As part of the relaunch of Qsymia and PANCREAZE we intend to launch the VIVUS HEALTH PLATFORM • We believe that an integrated approach to weight management yields a higher percentage
Slide 19: VIVUS Health Platform – Launching Q1 2019
Strategic Development VIVUS HEALTH PLATFORM – Launching Q1 2019 Use Case Dependent NUTRITIONAL SCIENCE PHARMACEUTICAL SCIENCE Monitors PATIENT • • • • • • Sleep EKG Weight BMI BP Dietary Inputs ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 20
Slide 20: VIVUS Health Platform – Why?
Strategic Development VIVUS HEALTH PLATFORM – WHY? ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 21 • The VIVUS HEALTH PLATFORM will allow VIVUS to partner with MD’s, Dieticians, Nutritionists, Self Insured Employers, Private and Public Insurers and most importantly Patients to
Slide 21: Financial Snapshot
Financials Financial Snapshot (in $MM, except per share data) Company Name Ticker Current Share Price (1/2/2019) 52 Week High 52 Week Low Vivus, Inc VVUS $ $ $ 2.34 9.90 2.52 Plus: Debt (Principal value) Convertible Notes, due 2020 Senior Secured Notes, due 2024 Less Cash and Investments 190.0 110.0
Slide 22: Operating Results
Financials Operating Results 2017 Revenue: 2017 2018 Q4 Q1 Q2 Q3 LTM (in $MMs, except per share data) License and milestone revenue 7,500 - - - - - Royalty revenue 2,483 664 585 668 1,126 3,043 Operating expenses: Amortization of intangible asset 544 91 91 1,273 3,638 5,093 Selling and marketing 16,
Slide 23: Management Focus Next Months
Overview Management Focus Next 24 Months ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 24 •Drive Qsymia revenue and profitability with the Transformative Pharmaceutical Operating Model •Re-launch PANCREAZE in Q1 2019 •New sales team and excellent market insights •Leverage the T
Slide 24: Thank You
25 VIVUS Thank You ©2019 VIVUS Inc. llrightsreserved. INNOVATIVE THERAPIES-NOVEL PRODUCTS | wwrw.vivus.com | Nasdaq: WUS